FDA Accepts BLA for Datopotamab Deruxtecan for Nonsquamous N

The application is based on results of the phase 3 TROPION-Lung01 trial of datopotamab deruxtecan in nonsquamous non–small cell lung cancer (NSCLC), first presented at the 2023 European Society for Medical Oncology Congress.

Related Keywords

California , United States , American , Caffreym Trastuzumab , Daiichi Sankyo , Los Angeles , Susan Galbraith , Aaron Lisberg , University Of California , Astrazeneca , European Society For Medical Oncology , Medical Oncology , Biologics License Application , American Journal , Nsclc , Non Small Cell Lung Cancer , Datopotamab Deruxtecan , Antibody Drug Conjugates ,